Inactive Instrument

News Amarillo Biosciences, Inc. Other OTC

Equities

AMAR

US02301P2056

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	Mar. 19	CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	Mar. 15	CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	Mar. 11	MT
Top Premarket Decliners	Mar. 11	MT
Ainos : Reports Full Year 2023 Financial Results - Form 8-K	Mar. 08	PU
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Top Premarket Gainers	Mar. 08	MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	Feb. 05	MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	Feb. 05	CI
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th	Feb. 01	AQ
Ainos Announces $1.75 Million Follow-On Funding	Jan. 25	AQ
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	Jan. 12	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Ainos Regains Compliance With Nasdaq Listing Rule	Jan. 02	MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	Dec. 26	CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	Dec. 22	CI
Ainos, Inc. Announces Stock Consolidation	Dec. 13	AQ
Ainos : Private Placement - Form 8-K	Nov. 24	PU
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	Nov. 21	MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	Nov. 21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amarillo Biosciences, Inc. Other OTC

Equities

AMAR

US02301P2056

Summary

Filters